Sugi Predict

Sugi Predict / Compounds / SCHEMBL3249107

SCHEMBL3249107

SCHEMBL3249107

CC(C)(C)OC(=O)N1CCC(OCc2ccccc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STS P08842 1/20 0.58
▸ GPR119 Q8TDV5 4/20 0.57
▸ KDM4E B2RXH2 1/20 0.55
▸ PKM P14618 1/20 0.55
▸ PRMT5 O14744 2/20 0.53
▸ WDR77 Q9BQA1 1/20 0.53
▸ JAK2 O60674 1/20 0.52
▸ JAK1 P23458 1/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ GAA P10253 1/20 0.52
▸ THRB P10828 1/20 0.52
▸ NPC1 O15118 2/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ YAP1 P46937 2/20 0.51
▸ LMNA P02545 1/20 0.51
▸ GRIN2D O15399 1/20 0.50
▸ GRIN3B O60391 1/20 0.50
▸ GRIN1 Q05586 1/20 0.50
▸ GRIN2A Q12879 1/20 0.50
▸ GRIN2B Q13224 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8131049 0.95 STS (0.54) STSGPR119KDM4EPKMPRMT5
SCHEMBL21493553 0.95 STS (0.54) STSGPR119KDM4EPKMPRMT5
SCHEMBL697850 0.92 JAK2 (0.55) STSGPR119KDM4EPKMPRMT5
SCHEMBL20503925 0.92 JAK2 (0.55) STSGPR119KDM4EPKMPRMT5
SCHEMBL942191 0.92 JAK2 (0.55) STSGPR119KDM4EPKMPRMT5
SCHEMBL21458596 0.89 STS (0.53) STSGPR119KDM4EPKMPRMT5
SCHEMBL29079623 0.89 GPR119 (0.61) STSGPR119KDM4EPKMJAK2
SCHEMBL27379730 0.89 YAP1 (0.54) STSGPR119KDM4EPKMPRMT5
SCHEMBL9483382 0.88 GPR119 (0.58) GPR119PRMT5WDR77SMN1; SMN2
SCHEMBL22906856 0.88 STS (0.52) STSGPR119KDM4EPKMPRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025217125-A2 NOVEL LIPIDS FOR DELIVERY OF NUCLEIC ACID THERAPEUTICS POPVAX PRIVATE LIMITED (IN) 2025-10-16 — — WO disclosed
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-04-10 — — US disclosed
US-20250059188-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-02-20 — — US disclosed
EP-4452977-A1 ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2024-10-30 — — EP disclosed
EP-4452978-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2024-10-30 — — EP disclosed
US-12065445-B2 CDK2 inhibitors and methods of using the same CEDILLA THERAPEUTICS, INC. (US) 2024-08-20 — — US disclosed
US-20240174680-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-05-30 — — US disclosed
WO-2024061853-A1 FLUORESCENT PROBES FOR MAGL F. HOFFMANN-LA ROCHE AG (CH) 2024-03-28 — — WO disclosed
EP-4284365-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2023-12-06 — — EP disclosed
CN-117177744-A CDK2 inhibitors and methods of use thereof 塞迪拉治疗股份有限公司 2023-12-05 — — CN disclosed
EP-1467995-A2 PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 — — EP disclosed
US-20030229067-A1 Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-12-11 — — US disclosed
WO-2003053361-A2 PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 — — WO disclosed
US-5998440-A Azetidine, pyrrolidine and piperidine derivatives MERCK SHARPE & DOHME LTD. (GB) 1999-12-07 — — US disclosed
EP-0689535-B1 BENZIMIDAZOLE DERIVATIVES MERCK SHARP & DOHME (GB) 1998-09-23 — — EP disclosed
EP-0861244-A1 AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 1998-09-02 — — EP disclosed
US-5714498-A Benzimidazole derivatives MERCK, SHARP, & DOHME, LTD. (GB) 1998-02-03 — — US disclosed
WO-1997018201-A1 AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1997-05-22 — — WO disclosed
EP-0689535-A1 BENZIMIDAZOLE DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 1996-01-03 — — EP disclosed
WO-1994021615-A1 BENZIMIDAZOLE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1994-09-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229067-A1 Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use ADORA2B, OXER1, CNR1 STS 2593/4885GPR119 328/4885KDM4E 4046/4885
US-20240174680-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CDK2, CDK20, CDK2AP2 STS 3464/4885GPR119 4282/4885KDM4E 2149/4885
US-20250115598-A1 BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 STS 1347/4885GPR119 2316/4885KDM4E 1176/4885
US-20250059188-A1 ARYLSULPHONAMIDE COMPOUNDS MLKL, CASP1, CASP9 STS 1911/4885GPR119 1420/4885KDM4E 1651/4885
US-12065445-B2 CDK2 inhibitors and methods of using the same CDK2, CDK20, CDK1 STS 2740/4885GPR119 4190/4885KDM4E 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.